Skip to main content

Table 6 The frequencies of antifungal usage in patients from 2013 to 2017

From: Surveillance study of the prevalence, species distribution, antifungal susceptibility, risk factors and mortality of invasive candidiasis in a tertiary teaching hospital in Southwest China

 Antifungal agent

Patients n (%)c

Total (n = 243)

2013 (n = 20)

2014 (n = 29)

2015 (n = 44)

2016 (n = 74)

2017 (n = 76)

 Amphotericin B(i.v.)

49 (20.2)

6(30.0%)

5 (17.2)

13 (29.5)

17 (23.0)

8 (10.5)

 Fluconazolea(i.v.)

122 (52.8)

11 (55.0%)

20 (69.0)

19 (43.2)

30 (40.5)

42 (55.3)

 Voriconazole(i.v.)

84 (34.6)

8 (40.0)

10 (34.5)

15 (34.1)

27 (36.5)

24 (31.6)

 otherb

20(13.3)

0

0

0

15(20.3)

5(6.5)

  1. i.v. intravenous
  2. aC. krusei is excluded
  3. bother including caspofungin (intravenous) and itraconazole (oral)
  4. cSome patients used more than two kind of antifungal drugs during the course of treatment
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us